Bild von freepikDutch venture capital firm Forbion revealed that its BioEconomy Fund I has amassed €164.5m. This surpasses the fund’s initial target of €150m, highlighting the increasing interest from investors in the commercial viability of biotech solutions that tackle worldwide sustainability issues.
Tag Archive for: Forbion
Jeyaratnam Caniceus/Pixabay.comVerdiva Bio, a London-based biotech, has raised an extraordinary US$410m in its oversubscribed Series A round, making it potentially the largest Series A ever raised by a U.K.-based biotech company, according to CEO Khurem Farooq.
Image by freepikPurespring Therapeutics, a pioneering gene therapy company focused on transforming kidney disease treatment, has raised £80 (€96m) in an oversubscribed Series B round. Led by Sofinnova Partners, this funding also drew support from Gilde Healthcare, Forbion, British Patient Capital, and Syncona Limited.
Stijnstijl fotografieDutch Forbion has announced its largest fundraising to date, with Forbion’s Growth Opportunities Fund III raising €1.2bn and Forbion Ventures Fund VII raising €890m.
Forbion BioEconomy represents a strategic expansion of Forbion’s investment scope in biotech and in the life sciences sector to address challenges relating to the environment, the growing need for a sustainable supply of food and the rapid depletion of natural resources.
Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located in San Diego, USA.